https://www.fda.gov/news-events/press-a ... depression
Approved on August 4th
PFS Foundation has been monitoring this one. It messes with the GABAa receptor. I am not sure why the foundation thinks it could help but hopefully they will comment on it soon. Side effect list looks typically disheartening.
SAGE-217 Approved
-
- Posts: 38
- Joined: Sat Apr 22, 2017 9:51 pm
- Contact:
Re: SAGE-217 Approved
Basically new benzodiazepine
-
- Posts: 196
- Joined: Sat Sep 23, 2017 5:21 pm
- Contact:
Re: SAGE-217 Approved
Glad to see a non serotonergic antidepressant hit the market.
Seems to have pretty good efficacy. I like the mechanism.
Seems to have pretty good efficacy. I like the mechanism.
-
- Posts: 289
- Joined: Sat Mar 30, 2019 8:02 pm
- Contact:
Re: SAGE-217 Approved
Zurzuvae is a neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM).
Zurzuvae is thought to work by rebalancing brain networks responsible for functions such as mood, arousal, behavior, and cognition. Some health conditions, such as depression, are thought to be due to imbalances in GABA (Gamma-aminobutyric acid). GABA is a chemical messenger (neurotransmitter) in the brain and spinal cord (central nervous system). Zurzuvae is a neuroactive steroid that acts on the GABA-A receptors as a positive allosteric modulator.
Who is online
Users browsing this forum: No registered users and 2 guests